Leap's lead candidate shows positive action in esophageal cancer study [Seeking Alpha]
Leap Therapeutics, Inc. (LPTX)
Last leap therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.leaptx.com
Company Research
Source: Seeking Alpha
Interim results from a Phase 1/2 clinical trial evaluating Leap Therapeutics' ( LPTX ) lead drug DKN-01, combined with Celgene's ( CELG ) Abraxane (paclitaxel), in patients with advanced esophageal cancer showed a treatment effect. The dat are being presented at the SITC annual meeting in Washington, DC. 59 patients who had received one-to-seven prior lines of therapies were enrolled. The overall response rate (ORR) was 46.7% (n=7/15) in 15 evaluable patients in a second line setting. Median progression-free survival (PFS) was 19.6 weeks while median overall survival (OS) was 61.1 weeks. Results from a Phase 3 study, RAINBOW, evaluating paclitaxel alone in second-line gastroesophageal junction or gastric cancer showed a 16.1% response rate and median PFS and OS of 2.9 months and 7.4 months, respectively. In a subgroup (n=12) of heavily pretreated esophageal squamous cell carcinoma patients, the combination of DKN-01 and paclitaxel produced a 33.3% response rate
Show less
Read more
Impact Snapshot
Event Time:
LPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LPTX alerts
High impacting Leap Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LPTX
News
- Leap Therapeutics Announces $40 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Leap Therapeutics Announces $40 Million Private PlacementPR Newswire
- Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Leap Therapeutics, Inc. (NASDAQ: LPTX) had its price target lowered by analysts at Robert W. Baird from $11.00 to $9.00. They now have an "outperform" rating on the stock.MarketBeat
- Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
LPTX
Earnings
- 3/18/24 - Beat
LPTX
Sec Filings
- 4/19/24 - Form SC
- 4/19/24 - Form 3
- 4/11/24 - Form 8-K
- LPTX's page on the SEC website